-
1
-
-
78349273297
-
Dual inhibition of PI3K and mTORC1/2 signalling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia
-
Chapuis, N., Tamburini, J., Green, A.S., Vignon, C., Bardet, V., Neyret, A., Pannetier, M., Willems, L., Park, S., Macone, A., Maira, M.S., Ifrah, N., Dreyfus, F., Herault, O., Lacombe, C., Mayeux, P. & Bouscary, D. (2010a) Dual inhibition of PI3K and mTORC1/2 signalling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clinical Cancer Research, 16, 5424-5435.
-
(2010)
Clinical Cancer Research
, vol.16
, pp. 5424-5435
-
-
Chapuis, N.1
Tamburini, J.2
Green, A.S.3
Vignon, C.4
Bardet, V.5
Neyret, A.6
Pannetier, M.7
Willems, L.8
Park, S.9
Macone, A.10
Maira, M.S.11
Ifrah, N.12
Dreyfus, F.13
Herault, O.14
Lacombe, C.15
Mayeux, P.16
Bouscary, D.17
-
2
-
-
77957994045
-
Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies
-
Chapuis, N., Tamburini, J., Green, A.S., Willems, L., Bardet, V., Park, S., Lacombe, C., Mayeux, P. & Bouscary, D. (2010b) Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia, 24, 1686-1699.
-
(2010)
Leukemia
, vol.24
, pp. 1686-1699
-
-
Chapuis, N.1
Tamburini, J.2
Green, A.S.3
Willems, L.4
Bardet, V.5
Park, S.6
Lacombe, C.7
Mayeux, P.8
Bouscary, D.9
-
3
-
-
77954659127
-
Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial
-
Chevallier, P., Fornecker, L., Lioure, B., Bene, M.C., Pigneux, A., Recher, C., Witz, B., Fegueux, N., Bulabois, C.E., Daliphard, S., Bouscary, D., Vey, N., Delain, M., Bay, J.O., Turlure, P., Bernard, M., Himberlin, C., Luquet, I., Ifrah, N. & Harousseau, J.L. (2010) Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial. Leukemia, 24, 1380-1385.
-
(2010)
Leukemia
, vol.24
, pp. 1380-1385
-
-
Chevallier, P.1
Fornecker, L.2
Lioure, B.3
Bene, M.C.4
Pigneux, A.5
Recher, C.6
Witz, B.7
Fegueux, N.8
Bulabois, C.E.9
Daliphard, S.10
Bouscary, D.11
Vey, N.12
Delain, M.13
Bay, J.O.14
Turlure, P.15
Bernard, M.16
Himberlin, C.17
Luquet, I.18
Ifrah, N.19
Harousseau, J.L.20
more..
-
4
-
-
2342489456
-
eIF-4E expression and its role in malignancies and metastases
-
De Benedetti, A. & Graff, J.R. (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene, 23, 3189-3199.
-
(2004)
Oncogene
, vol.23
, pp. 3189-3199
-
-
De Benedetti, A.1
Graff, J.R.2
-
5
-
-
77956275419
-
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression
-
Furic, L., Rong, L., Larsson, O., Koumakpayi, I.H., Yoshida, K., Brueschke, A., Petroulakis, E., Robichaud, N., Pollak, M., Gaboury, L.A., Pandolfi, P.P., Saad, F. & Sonenberg, N. (2010) eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 107, 14134-14139.
-
(2010)
Proceedings of the National Academy of Sciences of the United States of America
, vol.107
, pp. 14134-14139
-
-
Furic, L.1
Rong, L.2
Larsson, O.3
Koumakpayi, I.H.4
Yoshida, K.5
Brueschke, A.6
Petroulakis, E.7
Robichaud, N.8
Pollak, M.9
Gaboury, L.A.10
Pandolfi, P.P.11
Saad, F.12
Sonenberg, N.13
-
6
-
-
0035312747
-
Regulation of translation initiation by FRAP/mTOR
-
Gingras, A.C., Raught, B. & Sonenberg, N. (2001) Regulation of translation initiation by FRAP/mTOR. Genes and Development, 15, 807-826.
-
(2001)
Genes and Development
, vol.15
, pp. 807-826
-
-
Gingras, A.C.1
Raught, B.2
Sonenberg, N.3
-
7
-
-
77958027783
-
Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer
-
Hsieh, A.C. & Ruggero, D. (2010) Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clinical Cancer Research, 16, 4914-4920.
-
(2010)
Clinical Cancer Research
, vol.16
, pp. 4914-4920
-
-
Hsieh, A.C.1
Ruggero, D.2
-
8
-
-
42949142189
-
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
-
Schlenk, R.F., Dohner, K., Krauter, J., Frohling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Spath, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A. & Dohner, H. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New England Journal of Medicine, 358, 1909-1918.
-
(2008)
New England Journal of Medicine
, vol.358
, pp. 1909-1918
-
-
Schlenk, R.F.1
Dohner, K.2
Krauter, J.3
Frohling, S.4
Corbacioglu, A.5
Bullinger, L.6
Habdank, M.7
Spath, D.8
Morgan, M.9
Benner, A.10
Schlegelberger, B.11
Heil, G.12
Ganser, A.13
Dohner, H.14
-
9
-
-
38049187096
-
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
-
Tamburini, J., Chapuis, N., Bardet, V., Park, S., Sujobert, P., Willems, L., Ifrah, N., Dreyfus, F., Mayeux, P., Lacombe, C. & Bouscary, D. (2008) Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood, 111, 379-382.
-
(2008)
Blood
, vol.111
, pp. 379-382
-
-
Tamburini, J.1
Chapuis, N.2
Bardet, V.3
Park, S.4
Sujobert, P.5
Willems, L.6
Ifrah, N.7
Dreyfus, F.8
Mayeux, P.9
Lacombe, C.10
Bouscary, D.11
-
10
-
-
70349576526
-
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
-
Tamburini, J., Green, A.S., Bardet, V., Chapuis, N., Park, S., Willems, L., Uzunov, M., Ifrah, N., Dreyfus, F., Lacombe, C., Mayeux, P. & Bouscary, D. (2009) Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood, 114, 1618-1627.
-
(2009)
Blood
, vol.114
, pp. 1618-1627
-
-
Tamburini, J.1
Green, A.S.2
Bardet, V.3
Chapuis, N.4
Park, S.5
Willems, L.6
Uzunov, M.7
Ifrah, N.8
Dreyfus, F.9
Lacombe, C.10
Mayeux, P.11
Bouscary, D.12
|